Matthijs Vlasveld studied Bio-Pharmaceutical Sciences at Leiden University. During his MSc program, he specialized in toxicology, with a focus on cellular mechanisms of hepatotoxicity.
The first internship of Matthijs focused on the synergistic adverse reaction between the inflammatory response and carbamazepine as hepatotoxic drug and genes that regulate this response. To obtain a broader experience in the field of cell biology, he went to Konstanz to learn more about mechanistic research and different cell types.
In May 2018, Matthijs started his PhD at the division of drug discovery and safety. His project focusses on the mechanisms behind adverse outcome by drug-like chemicals and the development of a tool that better predicts biomarkers that indicate these adverse reactions.
No relevant ancillary activities